ScreenPoint Medical, a healthcare technology company, has raised €11.9 million in funding from existing investors, including Insight Partners and Siemens Healthineers, alongside €1.7 million in non-dilutive research grants.
The combined €13.6 million will support product development, international expansion, and continued advancement of AI-driven tools for breast cancer detection and risk assessment.
What The Company Does
Founded in 2014 as a spin-off from Radboud University Medical Centre by Professors Nico Karssemeijer and Sir Michael Brady, ScreenPoint Medical develops artificial intelligence solutions for breast imaging. Its technology is designed to support radiologists in detecting cancer earlier, reducing diagnostic uncertainty, and enabling more tailored patient care.
The company’s core product, Transpara, is an AI-based software suite that assists in the analysis of both 2D and 3D mammograms. By identifying patterns that may indicate malignancies, the platform aims to improve diagnostic accuracy while streamlining clinical workflows.
Transpara is currently deployed in more than 30 countries and has been used to analyse over 12 million mammograms. Clinical studies indicate that the software can increase cancer detection rates while reducing the workload associated with traditional screening processes.
The technology has also been evaluated in large-scale clinical research, including the MASAI randomised controlled trial published in The Lancet, which reported improved outcomes compared to standard double reading practices.
Advertisement
Market Context / Industry Background
Breast cancer remains one of the most common cancers globally, with early detection playing a critical role in improving survival rates. However, screening programmes face increasing pressure due to rising demand and limited radiology capacity.
Artificial intelligence is being integrated into medical imaging to address these challenges. AI-assisted diagnostics can help reduce false positives and false negatives while supporting clinicians in managing growing volumes of imaging data.
In Europe and other developed healthcare systems, there is a growing emphasis on precision medicine and personalised care pathways. Technologies that combine diagnostic accuracy with workflow efficiency are increasingly gaining traction as healthcare providers seek to balance quality of care with operational and financial constraints.
ScreenPoint Medical operates within this rapidly evolving landscape, focusing on embedding advanced AI directly into clinical practice to enhance both patient-level outcomes and population-wide screening programmes.
Founder / Investor Commentary
CEO Pieter Kroese stated that the funding reflects confidence in the company’s strategy and progress, noting that ScreenPoint Medical is positioned to scale internationally while continuing to develop solutions that support both clinicians and patients across the full spectrum of breast cancer care.
Dr Robert Epstein, Health Care Senior Advisor at Insight Partners, highlighted the broader clinical potential of the company’s technology. He pointed to the opportunity for AI to enable more personalised care, describing its impact as significant at both individual patient and population levels. He added that ScreenPoint Medical is building a more integrated and comprehensive approach to breast imaging.
Growth Plans / Use Of Funds
The newly secured funding will be directed toward further development of ScreenPoint Medical’s product portfolio, with a focus on enhancing its AI capabilities and expanding clinical applications.
The company also plans to accelerate its international growth, increasing adoption across healthcare systems in new and existing markets. Strengthening partnerships with clinical institutions and technology providers is expected to be part of this expansion strategy.
In addition, the research grants will support ongoing scientific development, enabling the company to validate and refine its technology through continued clinical studies.
About ScreenPoint Medical
ScreenPoint Medical is a healthcare technology company focused on artificial intelligence for breast imaging. Founded in 2014 and headquartered in Nijmegen, Netherlands, the company develops solutions that support early cancer detection, improve risk assessment, and enable more personalised care pathways through advanced image analysis.
